These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38994836)
1. Unveiling the Correlation Between the Membrane Assembly of P-gp and Drug Resistance in Multiple Myeloma Using Super-Resolution Fluorescence Imaging. Chen J; Du Y; Hou H; Li W; Sun C; Liang F; Wang H Anal Chem; 2024 Jul; 96(29):11673-11681. PubMed ID: 38994836 [TBL] [Abstract][Full Text] [Related]
2. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582 [TBL] [Abstract][Full Text] [Related]
3. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. O'Connor R; Ooi MG; Meiller J; Jakubikova J; Klippel S; Delmore J; Richardson P; Anderson K; Clynes M; Mitsiades CS; O'Gorman P Cancer Chemother Pharmacol; 2013 May; 71(5):1357-68. PubMed ID: 23589314 [TBL] [Abstract][Full Text] [Related]
4. A multidrug-resistant P-glycoprotein assembly revealed by tariquidar-probe's super-resolution imaging. Chen J; Li H; Wu Q; Zhao T; Xu H; Sun J; Liang F; Wang H Nanoscale; 2021 Oct; 13(40):16995-17002. PubMed ID: 34617531 [TBL] [Abstract][Full Text] [Related]
5. The role of P-glycoprotein in drug resistance in multiple myeloma. Abraham J; Salama NN; Azab AK Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978 [TBL] [Abstract][Full Text] [Related]
6. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance. Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509 [TBL] [Abstract][Full Text] [Related]
7. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174 [TBL] [Abstract][Full Text] [Related]
8. LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance. Zhitomirsky B; Farber H; Assaraf YG J Cell Mol Med; 2018 Apr; 22(4):2131-2141. PubMed ID: 29377455 [TBL] [Abstract][Full Text] [Related]
9. A Y Wang Y; Jiang Z; Yuan B; Tian Y; Xiang L; Li Y; Yang Y; Li J; Wu A Biomater Sci; 2019 Nov; 7(11):4748-4757. PubMed ID: 31508613 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance. Tóth S; Szepesi Á; Tran-Nguyen VK; Sarkadi B; Német K; Falson P; Di Pietro A; Szakács G; Boumendjel A Molecules; 2020 Feb; 25(3):. PubMed ID: 32050702 [TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Patel NR; Rathi A; Mongayt D; Torchilin VP Int J Pharm; 2011 Sep; 416(1):296-9. PubMed ID: 21703341 [TBL] [Abstract][Full Text] [Related]
12. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells. Dinić J; Podolski-Renić A; Jovanović M; Musso L; Tsakovska I; Pajeva I; Dallavalle S; Pešić M Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527404 [TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Binkhathlan Z; Lavasanifar A Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096 [TBL] [Abstract][Full Text] [Related]
14. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines. Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139 [TBL] [Abstract][Full Text] [Related]
15. Psorospermin structural requirements for P-glycoprotein resistance reversal. Carey SS; Gleason-Guzman M; Gokhale V; Hurley LH Mol Cancer Ther; 2008 Nov; 7(11):3617-23. PubMed ID: 19001443 [TBL] [Abstract][Full Text] [Related]
16. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859 [TBL] [Abstract][Full Text] [Related]
17. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice. Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694 [TBL] [Abstract][Full Text] [Related]
18. Morin reverses P-glycoprotein-mediated multidrug-resistance in KBChR-8-5 cancer cell lines. Zhao Y; Xu S; Hao W; Fu Y Cell Biochem Funct; 2024 Jul; 42(5):e4083. PubMed ID: 38938150 [TBL] [Abstract][Full Text] [Related]
19. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746 [TBL] [Abstract][Full Text] [Related]
20. Structural and functional aspects of P-glycoprotein and its inhibitors. Mollazadeh S; Sahebkar A; Hadizadeh F; Behravan J; Arabzadeh S Life Sci; 2018 Dec; 214():118-123. PubMed ID: 30449449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]